2024 - Diversity Action Plan Success: From Planning to Execution

In this webinar, the expert speakers will provide a clear map of best practices to optimize diversity action plans right from infrastructure to execution.
Diversity action plans are a hot topic in the clinical development process, particularly now that the US Food and Drug Administration (FDA) has released its revised guidance, Diversity Action Plans to Improve Enrollment of Participants from Underrepresented Populations in Clinical Studies, in June 2024.
This updated draft provides a much more robust blueprint for what is expected from clinical study sponsors. However, what is missing and what some sponsors have not yet realized is that diversity action plans do not exist in a vacuum. The most successful plans are developed within an ecosystem that lends itself to supporting new and ambitious ways to engage study participants who have historically not been part of clinical research but who have been disproportionately burdened by diseases.
Through longitudinal qualitative research, including in-depth interviews and collaborations with pharmaceutical and biotechnology companies of different size market caps, employee sizes and therapeutic focus (i.e., rare and high prevalence disorders), nine best practices have emerged that, when implemented, can improve the likelihood of developing a successful diversity action plan.
Additionally, the expert speakers will highlight key areas of the revised FDA guidance that can help sponsors successfully develop, execute and evaluate their diversity action plans.
Register for this webinar to learn more about how impactful diversity action plans that will positively differentiate studies can be developed.
Keywords: Clinical Trials, FDA, Clinical Research, Patient Recruitment, Regulatory, Diversity, Patient Diversity, Clinical Trial Diversity, Diversity and Inclusion, Diversity and Inclusion in Clinical Trials, Diversity Action Plans (DAPs)